Literature DB >> 12406893

A chemically defined culture of VEGFR2+ cells derived from embryonic stem cells reveals the role of VEGFR1 in tuning the threshold for VEGF in developing endothelial cells.

Masanori Hirashima1, Minetaro Ogawa, Satomi Nishikawa, Kazuyoshi Matsumura, Kotomi Kawasaki, Masabumi Shibuya, Shin-Ichi Nishikawa.   

Abstract

Vascular endothelial growth factor (VEGF) is a major growth factor for developing endothelial cells (ECs). Embryonic lethality due to haploinsufficiency of VEGF in the mouse highlighted the strict dose dependency of VEGF on embryonic vascular development. Here we investigated the dose-dependent effects of VEGF on the differentiation of ES cell-derived fetal liver kinase 1 (Flk-1)/VEGF receptor 2(+) (VEGFR2(+)) mesodermal cells into ECs on type IV collagen under a chemically defined serum-free condition. These cells could grow even in the absence of VEGF, but differentiated mostly into mural cells positive for alpha-smooth muscle actin. VEGF supported in a dose-dependent manner the differentiation into ECs defined by the expression of VE-cadherin, platelet-endothelial cell adhesion molecule 1 (PECAM-1)/ CD31, CD34, and TIE2/TEK. VEGF requirement was greater at late than at early phase of culture during EC development, whereas response of VEGFR2(+) cells to VEGF-E, which is a virus-derived ligand for VEGFR2 but not for Flt-1/VEGFR1, was not dose sensitive even at late phase of culture. Delayed expression of VEGFR1 correlated with increased dose dependency of VEGF. These results suggested that greater requirement of VEGF in the maintenance than induction of ECs was due to the activity of VEGFR1 sequestering VEGF from VEGFR2 signal. The chemically defined serum-free culture system described here provides a new tool for assessing different factors for the proliferation and differentiation of VEGFR2(+) mesodermal cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406893     DOI: 10.1182/blood-2002-01-0003

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  The Potential of Stem Cells and Stem Cell-Derived Exosomes in Treating Cardiovascular Diseases.

Authors:  Jing Ni; Yuxi Sun; Zheng Liu
Journal:  J Cardiovasc Transl Res       Date:  2018-03-10       Impact factor: 4.132

2.  Preventive effect of dexamethasone gelatin sponge on the lumbosacral epidural adhesion.

Authors:  Fuming Tian; Changwu Dou; Songtao Qi; Liqun Zhao; Bo Chen; Haicheng Yan; Li Zhang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Hypoxia influences the vascular expansion and differentiation of embryonic stem cell cultures through the temporal expression of vascular endothelial growth factor receptors in an ARNT-dependent manner.

Authors:  Yu Han; Shu-Zhen Kuang; Alla Gomer; Diana L Ramirez-Bergeron
Journal:  Stem Cells       Date:  2010-04       Impact factor: 6.277

4.  [Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia].

Authors:  H M Kvasnicka; J Thiele; P Staib; K Engels; S Kriener; A Schmitt-Graeff
Journal:  Pathologe       Date:  2004-03       Impact factor: 1.011

5.  Renal cells from spermatogonial germline stem cells protect against kidney injury.

Authors:  Letizia De Chiara; Sharmila Fagoonee; Andrea Ranghino; Stefania Bruno; Giovanni Camussi; Emanuela Tolosano; Lorenzo Silengo; Fiorella Altruda
Journal:  J Am Soc Nephrol       Date:  2013-10-17       Impact factor: 10.121

Review 6.  Differentiation and diversification of vascular cells from embryonic stem cells.

Authors:  Jun K Yamashita
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

7.  Multifactorial Optimizations for Directing Endothelial Fate from Stem Cells.

Authors:  Drew E Glaser; William S Turner; Nicole Madfis; Lian Wong; Jose Zamora; Nicholas White; Samuel Reyes; Andrew B Burns; Ajay Gopinathan; Kara E McCloskey
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

Review 8.  Tissue engineering of blood vessel.

Authors:  Wen Jie Zhang; Wei Liu; Lei Cui; Yilin Cao
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

9.  Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma.

Authors:  Lauren T Kerr; Jacqueline F Donoghue; Alexander L Wilding; Terrance G Johns
Journal:  Sarcoma       Date:  2016-10-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.